CLINICAL_TRIALS
trial_result
· 2018-08-17
Clinical Trial Update: Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease [Phase 2]
Summary
A Phase 2 safety study of AT2220 (duvoglustat) for Pompe disease was terminated, with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amicus Therapeutics | Conditions: Pompe Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-08-17